Peregrine Pharmaceuticals and Affitech to develop six new antibodies

Published: 19-Nov-2004

US biopharmaceutical company Peregrine Pharmaceuticals and Norway-based human antibody therapeutics company Affitech have expanded their antibody collaboration to include the production of fully human monoclonal antibodies against up to six additional targets.


US biopharmaceutical company Peregrine Pharmaceuticals and Norway-based human antibody therapeutics company Affitech have expanded their antibody collaboration to include the production of fully human monoclonal antibodies against up to six additional targets.

The two companies are currently collaborating to produce fully human monoclonal antibodies against three targets that will be evaluated for the treatment of cancer and viral diseases. The expanded collaboration includes the production of up to an additional six human antibodies. The financial terms of the collaboration include research fees, milestone payments and royalties on net sales upon commercialisation.

'This collaboration with Affitech allows us to continue to expand our robust product pipeline over the next several years,' said Steven King, president and ceo of Peregrine. 'We believe our broad intellectual property combined with the expansion of clinical candidates creates a strong foundation of future opportunities.'

You may also like